ArticlePloS one2012

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

Robert A Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.